Trial Profile

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clopidogrel; Omeprazole
Indications Acute coronary syndromes; Atherosclerosis; Duodenal ulcer; Dyspepsia; Embolism and thrombosis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris; Zollinger-Ellison syndrome
Focus Pharmacodynamics; Pharmacogenomic

Most Recent Events

31 Jan 2018 Biomarkers information updated
20 May 2011 Planned end date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
30 Mar 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com